



Document No.: 50229-194

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of	:	Customer Number: 20277
	:	
Kenneth B. AIN, et al.	:	Confirmation Number: 7670
	:	
Serial No.: 09/606,042	:	Group Art Unit: 1642
	:	
Filed: June 29, 2000	:	Examiner: S. L. Rawlings
	:	
For: IODIDE UPTAKE RESTORATION IN THYROID CANCER	:	

INFORMATION DISCLOSURE STATEMENT

Mail Stop Information Disclosure Statement
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached form PTO-1449. It is respectfully requested that the documents be expressly considered during the prosecution of this application, and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.

In accordance with 37 CFR 1.17(p), please charge the fee of \$180.00 to Deposit Account No. 500417.

03/24/2004 AMONDAF1 00000002 500417 09606042

01 FC:1806 180.00 DA

Please charge any shortage in fees due in connection with the filing of this paper, including extension of time fees, to Deposit Account 500417 and please credit any excess fees to such deposit account.

Respectfully submitted,

MCDERMOTT, WILL & EMERY



Judith L. Toffenetti

Registration No. 39,048

600 13th Street, N.W.
Washington, DC 20005-3096
(202) 756-8000 JLT:ajb
Facsimile: (202) 756-8087
Date: March 19, 2004



SHEET 1 OF 1

INFORMATION DISCLOSURE
CITATION IN AN
APPLICATION

(PTO-1449)

ATTY. DOCKET NO.
50229-194SERIAL NO.
09/606,042APPLICANT
Kenneth B. AIN, et al.FILING DATE
June 29, 2000GROUP
1642

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS	CITE NO.	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US			
		US			
		US			
		US			
		US			
		US			
		US			
		US			
		US			
		US			
		US			
		US			
		US			
		US			
		US			

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS	CITE NO.	Foreign Patent Document Country Codes - Number 4 - Kind Codes (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Figures Appear	Translation	
						Yes	No

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER'S INITIALS	CITE NO.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
		KENNETH B. AIN, Management of undifferentiated thyroid cancer, Balliere's Clinical Endocrinology and Metabolism, Vol. 14, No. 4, pp. 615-629, 2000
		GEORGE J. DOVER, et al., The Effects of Variable Doses of 5-Azacytidine on Fetal Hemoglobin Production in Sickle Cell Anemia, The Red Cell: Sixth Ann Arbor Conference, pages 73-83
		SAMUEL CHARACHE, et al., Treatment of sickle cell anemia with 5-azacytidine results in increased fetal hemoglobin production and is associated with nonrandom hypomethylation of DNA around the γ - δ - β -Globin gene complex, Proc. Natl. Acad. Sci. USA, Vol. 80, pp. 4842-4846, August 1983, Medical Sciences
		TIMOTHY J. LEY, et al., 5-Azacytidine Selectively Increases γ -Globin Synthesis in a Patient With β^+ Thalassemia- The New England Journal of Medicine, Volume 307, Number 24
		TIMOTHY J. LEY, DNA Methylation and Globin Gene Expression in Patients Treated with 5-Azacytidine, Globin Gene Expression and Hematopoietic Differentiation, pages 457-474

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.